Elimor Brand‐Schieber

1.2k total citations
28 papers, 924 citations indexed

About

Elimor Brand‐Schieber is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine and Physiology. According to data from OpenAlex, Elimor Brand‐Schieber has authored 28 papers receiving a total of 924 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Psychiatry and Mental health, 13 papers in Pathology and Forensic Medicine and 8 papers in Physiology. Recurrent topics in Elimor Brand‐Schieber's work include Migraine and Headache Studies (16 papers), Trigeminal Neuralgia and Treatments (11 papers) and Sympathectomy and Hyperhidrosis Treatments (7 papers). Elimor Brand‐Schieber is often cited by papers focused on Migraine and Headache Studies (16 papers), Trigeminal Neuralgia and Treatments (11 papers) and Sympathectomy and Hyperhidrosis Treatments (7 papers). Elimor Brand‐Schieber collaborates with scholars based in United States, United Kingdom and India. Elimor Brand‐Schieber's co-authors include Peter Werner, John R. Falck, Sagar Munjal, Mong-Heng Wang, Barbara A. Zand, Xuandai Nguyen, Michal L. Schwartzman, Narayanan Balu, Timothy Hsu and Heng Zou and has published in prestigious journals such as Nature Medicine, Neurology and Brain Research.

In The Last Decade

Elimor Brand‐Schieber

27 papers receiving 886 citations

Peers

Elimor Brand‐Schieber

PHYSI

PMH

BIOCH

PFM

Marina Zvartau‐Hind United States

Masaru Minami Japan

Flaubert Tchantchou United States

Jie Qi China

Catherine Malaplate‐Armand France

Dana M. Niedowicz United States

V. L. Raghavendra Rao Canada

M Lobisch Germany

Alister J. McNeish United Kingdom

Ruixian Guo China

Marina Zvartau‐Hind United States

Elimor Brand‐Schieber

785 ×2.8

PHYSI

223 ×0.9

PMH

77 ×0.3

BIOCH

423 ×2.2

126 ×0.7

PFM

Citations per year, relative to Elimor Brand‐Schieber Elimor Brand‐Schieber (= 1×) peers Marina Zvartau‐Hind

Countries citing papers authored by Elimor Brand‐Schieber

Since Specialization

Citations

This map shows the geographic impact of Elimor Brand‐Schieber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elimor Brand‐Schieber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elimor Brand‐Schieber more than expected).

Fields of papers citing papers by Elimor Brand‐Schieber

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Elimor Brand‐Schieber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elimor Brand‐Schieber. The network helps show where Elimor Brand‐Schieber may publish in the future.

Co-authorship network of co-authors of Elimor Brand‐Schieber

This figure shows the co-authorship network connecting the top 25 collaborators of Elimor Brand‐Schieber. A scholar is included among the top collaborators of Elimor Brand‐Schieber based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Elimor Brand‐Schieber. Elimor Brand‐Schieber is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goadsby, Peter J., Elimor Brand‐Schieber, Kristóf Nagy, et al.. (2025). Efficacy of ubrogepant and atogepant in males and females with migraine: A secondary analysis of randomized clinical trials. Cephalalgia. 45(2). 2235365666–2235365666. 1 indexed citations

Goadsby, Peter J., Jessica Ailani, David W. Dodick, et al.. (2025). Ubrogepant for the treatment of migraine prodromal symptoms: an exploratory analysis from the randomized phase 3 PRODROME trial. Nature Medicine. 31(7). 2179–2185. 4 indexed citations

Ailani, Jessica, Richard Lipton, Andrew Blumenfeld, et al.. (2024). Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: Results from the TANDEM study. Headache The Journal of Head and Face Pain. 65(6). 1005–1014. 4 indexed citations

Brand‐Schieber, Elimor, Richard B. Lipton, Andrew Blumenfeld, et al.. (2024). Safety and Tolerability of Ubrogepant for the Acute Treatment of Migraine in Participants Taking Atogepant for the Preventive Treatment of Episodic Migraine: Results from the TANDEM Trial (S22.005). Neurology. 102(7_supplement_1).

Goadsby, Peter J., Jessica Ailani, David W. Dodick, et al.. (2023). Efficacy of ubrogepant for the treatment of migraine symptoms during the prodrome (premonitory phase): Results from the prodrome trial. Journal of the Neurological Sciences. 455. 121630–121630. 3 indexed citations

Lipton, Richard B., Sagar Munjal, Elimor Brand‐Schieber, & Alan M. Rapoport. (2019). DFN-02, Sumatriptan 10 mg Nasal Spray with Permeation Enhancer, for the Acute Treatment of Migraine: A Randomized, Double-Blind, Placebo-Controlled Study Assessing Functional Disability and Subject Satisfaction with Treatment. CNS Drugs. 33(4). 375–382. 8 indexed citations

Landy, Stephen H., Sagar Munjal, Elimor Brand‐Schieber, & Alan M. Rapoport. (2018). Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: a multicenter, randomized, double-blind, placebo-controlled study. The Journal of Headache and Pain. 19(1). 69–69. 15 indexed citations

Landy, Stephen H., Sagar Munjal, Elimor Brand‐Schieber, & Alan M. Rapoport. (2018). Efficacy and safety of DFN-11 (sumatriptan injection, 3 mg) in adults with episodic migraine: an 8-week open-label extension study. The Journal of Headache and Pain. 19(1). 70–70. 7 indexed citations

Cady, Roger, et al.. (2017). Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine. The Journal of Headache and Pain. 18(1). 17–17. 26 indexed citations

10.

Andre, Anthony D., Elimor Brand‐Schieber, Margarita Ramírez, Sagar Munjal, & Rajesh Kumar. (2017). Subcutaneous sumatriptan delivery devices: comparative ease of use and preference among migraineurs. Patient Preference and Adherence. Volume 11. 121–129. 12 indexed citations

11.

Munjal, Sagar, et al.. (2017). A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine. The Journal of Headache and Pain. 18(1). 31–31. 21 indexed citations

12.

Andre, Anthony D., et al.. (2016). Human factors validation study of 3 mg sumatriptan autoinjector, for migraine patients. Medical Devices Evidence and Research. 9. 131–131. 10 indexed citations

13.

Chen, Laishun, et al.. (2015). Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans. Drug Design Development and Therapy. 9. 3293–3293. 6 indexed citations

14.

Farlow, Martin R., Felix Veloso, Margaret Moline, et al.. (2011). Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease. BMC Neurology. 11(1). 57–57. 65 indexed citations

15.

Farlow, Martin R., Stephen Salloway, Pierre N. Tariot, et al.. (2010). Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study. Clinical Therapeutics. 32(7). 1234–1251. 149 indexed citations

16.

Brand‐Schieber, Elimor, Peter Werner, Dumitru A. Iacobaş, et al.. (2005). Connexin43, the major gap junction protein of astrocytes, is down-regulated in inflamed white matter in an animal model of multiple sclerosis. Journal of Neuroscience Research. 80(6). 798–808. 101 indexed citations

17.

Brand‐Schieber, Elimor, et al.. (2004). Select ionotropic glutamate AMPA/kainate receptors are expressed at the astrocyte–vessel interface. Brain Research. 1007(1-2). 178–182. 41 indexed citations

18.

Brand‐Schieber, Elimor & Peter Werner. (2004). Calcium channel blockers ameliorate disease in a mouse model of multiple sclerosis. Experimental Neurology. 189(1). 5–9. 59 indexed citations

19.

Brand‐Schieber, Elimor & Peter Werner. (2003). AMPA/kainate receptors in mouse spinal cord cell‐specific display of receptor subunits by oligodendrocytes and astrocytes and at the nodes of Ranvier. Glia. 42(1). 12–24. 39 indexed citations

20.

Brand‐Schieber, Elimor & Peter Werner. (2003). (±)-α-Amino-3-hydroxy-5-methylisoxazole-4-propionic acid and kainate receptor subunit expression in mouse versus rat spinal cord white matter: similarities in astrocytes but differences in oligodendrocytes. Neuroscience Letters. 345(2). 126–130. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact